Brief: Basilea Plans To Submit A New Drug Application (Nda) In The U.S. Around Year End 2022

Basilea Pharmaceutica AG, Allschwil

28/06/2022 06:19

June 28 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * REG-BASILEA ANNOUNCES POSITIVE RESULTS OF PHASE 3
ERADICATE
STUDY WITH CEFTOBIPROLE IN STAPHYLOCOCCUS AUREUS BACTEREMIA
(SAB)
    * ANNOUNCES POSITIVE RESULTS OF PHASE 3 ERADICATE STUDY WITH
CEFTOBIPROLE IN STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB)
    * CEFTOBIPROLE MET PRIMARY AND SECONDARY EFFICACY ENDPOINTS
    * BASILEA PLANS TO SUBMIT A NEW DRUG APPLICATION (NDA) IN
U.S.
AROUND YEAR END 2022
    * COMPANY WILL EXPLORE POSSIBILITY FOR GAINING APPROVAL FOR
A
THIRD INDICATION BASED ON A PREVIOUSLY PERFORMED PHASE 3 STUDY
IN COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP)
    * TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PHASE 3
STUDY
ERADICATE

Source text for Eikon:  ID:nGNE9CzWzz 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))